Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Wood Group inches closer to a potential buyout, extends PUSU deadline

(Sharecast News) - Engineering and consulting firm Wood Group said on Monday that it has inched closer to a potential buyout after securing commercial alignment with bidder Sidara and its lenders on refinancing terms. Back in April, Sidara made a 35.0p per-share cash offer for Wood. Now, it said its board was working through the fine print, including a refreshed debt package that could extend maturities to 2028 and introduce new bonding facilities.

However, the refinancing hinges on Sidara making a firm offer for Wood Group, as well as shareholder approval and delivery of the first $250.0m liquidity tranche.

While most lenders were said to be on board with Sidara's offer, not all have signed on the dotted line as of yet. As a result, Wood said it may deploy a Scottish scheme of arrangement to make it all stick, which must be approved by a majority in number and 75% by value of committed lenders present and voting at the creditor meetings.

Wood Group also noted that a fallback plan was in place, in case of a shorter tenor extension, buying it time to explore alternative funding paths. Sidara now has until 25 August to put up or shut up.

As of 0825 BST, Wood shares remained suspended at 18.44p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.